FR21C1004I2 - Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe - Google Patents

Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe

Info

Publication number
FR21C1004I2
FR21C1004I2 FR21C1004C FR21C1004C FR21C1004I2 FR 21C1004 I2 FR21C1004 I2 FR 21C1004I2 FR 21C1004 C FR21C1004 C FR 21C1004C FR 21C1004 C FR21C1004 C FR 21C1004C FR 21C1004 I2 FR21C1004 I2 FR 21C1004I2
Authority
FR
France
Prior art keywords
treatment
ides
pyogenes
proteinase
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1004C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of FR21C1004I1 publication Critical patent/FR21C1004I1/fr
Application granted granted Critical
Publication of FR21C1004I2 publication Critical patent/FR21C1004I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR21C1004C 2005-06-09 2021-02-04 Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe Active FR21C1004I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment
PCT/EP2006/005454 WO2006131347A2 (fr) 2005-06-09 2006-06-08 Traitement

Publications (2)

Publication Number Publication Date
FR21C1004I1 FR21C1004I1 (fr) 2021-03-26
FR21C1004I2 true FR21C1004I2 (fr) 2022-01-14

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1004C Active FR21C1004I2 (fr) 2005-06-09 2021-02-04 Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe

Country Status (14)

Country Link
US (1) US8133483B2 (fr)
EP (1) EP1901773B1 (fr)
JP (1) JP5427409B2 (fr)
CN (1) CN105770871A (fr)
AT (1) ATE548049T1 (fr)
AU (1) AU2006256891B2 (fr)
BE (1) BE2021C505I2 (fr)
CA (1) CA2611646C (fr)
ES (1) ES2380950T3 (fr)
FR (1) FR21C1004I2 (fr)
NL (1) NL301089I2 (fr)
PL (1) PL1901773T3 (fr)
PT (1) PT1901773E (fr)
WO (1) WO2006131347A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1686302A (en) * 2000-12-21 2002-07-01 Shire Biochem Inc Streptococcus pyogenes antigens and corresponding dna fragments
EP2144681A4 (fr) * 2007-05-04 2011-10-05 Kurt G I Nilsson Matériau pour la séparation d'une biomolécule
CA2709029A1 (fr) 2007-12-21 2009-07-02 Bianca Eser Essai de stabilite d'anticorps
WO2010089126A2 (fr) 2009-02-09 2010-08-12 Roche Glycart Ag Analyse de motif de glycosylation d'immunoglobuline
CA2741965A1 (fr) * 2009-04-22 2010-10-28 Ofir Menashe Micro-organisme comprenant des particules et ses utilisations
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
PL3411389T3 (pl) 2016-02-04 2021-10-25 Genovis Ab Nowe proteazy streptokokowe
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
KR20220040476A (ko) * 2019-08-01 2022-03-30 메모리얼 슬로안 케터링 캔서 센터 개선된 면역치료법을 위한 세포 및 이의 용도
BR112021025438A2 (pt) * 2019-12-06 2022-06-21 Regeneron Pharma Composições de proteínas anti-vegf e métodos para produzir as mesmas
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
EP4215208A1 (fr) * 2020-09-21 2023-07-26 Shanghai Bao Pharmaceuticals Co., Ltd. Association pharmaceutique et son utilisation
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
WO2022221529A1 (fr) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Virions de vaa à polyploïde rationnel traversant la barrière hémato-encéphalique et déclenchant une réponse humorale réduite
EP4079848A1 (fr) 2021-04-22 2022-10-26 Genovis Ab Enzyme de clivage d'immunoglobuline
CN115998690A (zh) * 2022-11-10 2023-04-25 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2408691A1 (fr) * 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
NL301089I1 (fr) 2021-01-20
AU2006256891B2 (en) 2011-08-04
JP2008542418A (ja) 2008-11-27
CN105770871A (zh) 2016-07-20
US20100303781A1 (en) 2010-12-02
ATE548049T1 (de) 2012-03-15
FR21C1004I1 (fr) 2021-03-26
PL1901773T3 (pl) 2012-09-28
EP1901773A2 (fr) 2008-03-26
WO2006131347A3 (fr) 2007-05-31
BE2021C505I2 (fr) 2021-05-31
ES2380950T3 (es) 2012-05-21
AU2006256891A1 (en) 2006-12-14
US8133483B2 (en) 2012-03-13
EP1901773B1 (fr) 2012-03-07
NL301089I2 (nl) 2021-02-04
WO2006131347A2 (fr) 2006-12-14
CA2611646A1 (fr) 2006-12-14
PT1901773E (pt) 2012-06-06
CA2611646C (fr) 2015-08-11
JP5427409B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
FR21C1004I2 (fr) Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe
MA31920B1 (fr) 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation
EP1461081A4 (fr) Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
WO2008071418A3 (fr) Traitement
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
WO2007044756A3 (fr) Anticorps monoclonaux reconnaissant le ccr8 humain
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201000424A1 (ru) Антитела к il-23
WO2005016127A3 (fr) Reactifs peptidiques specifiques du prion
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
TR201907261T4 (tr) DKK-1 antikorları.
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
WO2008092905A3 (fr) Activation spécifique d'un lymphocyte t régulateur et son utilisation pour le traitement de l'asthme, d'une maladie allergique, d'une maladie auto-immune, d'un rejet de greffe et pour une induction de tolérance
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
GB0521762D0 (en) Diagnosis of neurodegenerative disorders
IL209338A0 (en) Pharmaceutical compositions containing anti-cd-3 antibodies
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
FR2889068B1 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
ATE412010T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
FR2858234B1 (fr) Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers
FR2856595B1 (fr) Methodes et compositions pour le traitement de deficits cognitifs.
WO2006103472A3 (fr) Facteur immunoregulateur soluble